INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Acorda Therapeutics, Inc. (ACOR)

NEW YORK, Nov. 15, 2017 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Acorda Therapeutics, Inc. ("Acorda" or the "Company") (NASDAQ: ACOR). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/acor1.  

The investigation concerns whether Acorda and certain of its officers and/or directors have violated Federal Securities Laws.

On November 15, 2017, Acorda revealed that it has stopped enrolling new patients in its Phase 3 trial of tozadenant due to 5 deaths that took place in the group of patients who took tozadenant. Following this news, Acorda stock dropped. Acorda also said that it added to the frequency of blood cell count monitoring for participants to weekly in its Phase 3 program of tozadenant for Parkinson's disease; "the Company took this action in response to cases of agranulocytosis, possibly drug-related, and in some cases associated with sepsis and death. Agranulocytosis is the absence of white blood cells, which fight infection. The Company also has paused new enrollment in the long-term safety studies, pending further discussion with the independent Data Safety Monitoring Board (DSMB) and the United States Food and Drug Administration (FDA)." Acorda also said that "[i]ncluding the previously conducted Phase 2b study, approximately 890 patients have been exposed to tozadenant and 234 have been exposed to placebo. This corresponds to approximately 300 patient years of tozadenant exposure and 75 patient-years of placebo. There have been seven cases of sepsis, all in the tozadenant groups, five of which were fatal. Four of the sepsis cases were associated with agranulocytosis, two had no white blood cell counts available at the time of the event and one had a high white blood cell count."

If you are aware of any facts relating to this investigation, or purchased Acorda shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/acor1.  You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.  

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]

SOURCE Bronstein, Gewirtz & Grossman, LLC

Related Links

http://www.bgandg.com